Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesa Laboratories, Inc. (MLAB) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Mesa is a Colorado corporation whose common stock is listed on The Nasdaq Stock Market LLC under the symbol MLAB, and it regularly submits reports and disclosures that detail its operations, governance, and financial condition.
Through this page, users can review current and historical filings such as Form 8-K reports, which Mesa uses to announce material events. Recent 8-K filings have covered topics including quarterly financial results, the creation of direct financial obligations under its credit facility, and the settlement of outstanding convertible notes. These filings often reference accompanying press releases that provide additional narrative and financial tables.
Investors can also find proxy materials, such as the company’s definitive proxy statement (DEF 14A). This document outlines items for shareholder vote at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity incentive plans. The proxy statement also describes Mesa’s board committees and aspects of its executive compensation framework.
In addition to these documents, Mesa’s SEC filings reference its credit facility, leverage metrics, and other capital structure details, giving readers insight into how the company finances its operations and manages debt. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain key sections, making it easier to understand complex disclosures without reading every page.
Users interested in MLAB can use this page to monitor new filings as they are posted to EDGAR, review past disclosures, and better understand the regulatory and governance context surrounding Mesa’s life science tools and quality control business.
Mesa Laboratories, Inc. drew $97 million under its existing senior secured Credit Facility on August 12, 2025, bringing total outstanding borrowings under that facility to $108 million. The company used the proceeds to fund settlement of its outstanding convertible notes that matured on August 15, 2025, in accordance with the indenture.
The Credit Facility carries interest at either a base rate or a SOFR rate plus a spread and matures on April 5, 2029. The filing references the full credit agreement previously filed on April 8, 2024, and includes a press release as Exhibit 99.1 dated August 18, 2025.
Shannon Hall, a director of Mesa Laboratories, reported stock-based compensation transactions dated 08/15/2025. The filing shows 1,404 restricted stock units (RSUs) vested on that date and were converted into 1,404 shares of common stock with a reported acquisition price of $0. After the transaction Hall beneficially owns 4,189 shares directly. The filing also reports an additional grant of 2,784 RSUs that vest on 08/15/2026 and are recorded as 2,784 shares of underlying common stock. The Form 4 was executed under power of attorney and signed on 08/18/2025.
Tony Tripeny, a director of Mesa Laboratories, reported transactions on 08/15/2025 that changed his beneficial ownership in the company's common stock. 1,404 shares were acquired upon vesting of Restricted Stock Units (RSUs) (price reported as $0) and 2,784 RSUs were granted that vest on 08/15/2026. After these transactions, he beneficially owns 4,083 shares. The Form 4 was filed with an 08/18/2025 signature executed by a power of attorney. All items reported relate to non-derivative shares and RSU awards described in the filing.
Mark Christopher Capone, a director of Mesa Laboratories, reported transactions on Form 4 showing equity from restricted stock units. On 08/15/2025 1,404 RSUs vested and were converted into 1,404 shares of common stock at a $0 price, increasing his reported beneficial ownership of common stock to 2,128 shares. The filing also reports an additional 2,784 RSUs that remain outstanding and vest on 08/15/2026. The Form 4 was executed under power of attorney by John Sakys and dated 08/18/2025. All transactions are routine equity compensation events; no cash purchase price was reported.
Jennifer Sadie Alltoft, a director of Mesa Laboratories, reported changes in her beneficial ownership on Form 4. On 08/15/2025 she had 1,404 restricted stock units (RSUs) vest and be converted into 1,404 shares of common stock at a $0 price, and she acquired an additional 2,784 RSUs that vest on 08/15/2026. After the transactions, she beneficially owned 4,878 shares directly.
The filing was signed under power of attorney by John Sakys on 08/18/2025. The transactions are compensation-related equity awards (vesting and new RSU grant) and reflect routine director equity compensation rather than open-market purchases or sales.
Mesa Laboratories (MLAB) filed its FY-26 Q1 10-Q for the quarter ended 30-Jun-2025. Net sales rose 2.4% YoY to $59.5 m, while gross margin slipped 200 bp to 62.0% as higher input and labor costs outweighed price and mix. Operating income fell 45% to $3.1 m, but a $6.1 m FX gain drove net income up 40% to $4.7 m, or diluted EPS of $0.85 (vs $0.62).
- Segment trends: Sterilization & Disinfection Control (+10.7% rev, 71.5% GM) offset declines in Biopharma Development (-4.3% rev, GM -11.4 ppt) and Clinical Genomics (-9.7% rev). Calibration Solutions grew 4.7% but margin contracted 4.4 ppt.
- Geography: U.S. sales +2.9% to $27.6 m; China -17% to $5.4 m; other regions +6.9%.
- Cash & debt: Cash fell to $21.3 m (-$6.0 m Q-to-Q) as operating cash flow shrank to $1.9 m (vs $10.7 m). Convertible notes of $97.5 m mature Aug-2025 and are now classified current; revolver balance rose to $14 m. Total leverage 1.8× EBITDA remains within covenants.
- Balance sheet: Inventories up 10.8% to $28.1 m; goodwill lifted by $6.3 m FX. Share count 5.50 m; dividend maintained at $0.16/sh (-$0.9 m cash).
- Guidance/risks: No formal outlook, but management cites tariff pressure, higher refinancing rates on revolver once notes are repaid, and segment-specific demand softness, particularly in China and BPD.
Overall, results show modest top-line expansion driven by SDC, but core profitability and cash generation weakened, and near-term refinancing risk rises as the convertible notes approach maturity.
On August 5, 2025, Mesa Laboratories, Inc. (Ticker: MLAB) filed a Form 8-K reporting that it issued a press release relating to its results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K.
The Form 8-K states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act and shall not be incorporated by reference into registration statements under the Securities Act. The filing also lists Exhibit 104 (Cover Page Interactive Data File). The report is signed by Gary M. Owens, President and Chief Executive Officer, dated August 5, 2025, and includes the registrant address and Nasdaq listing (symbol MLAB).
Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys reported multiple transactions on June 21, 2025. The transactions involved the vesting of 1,036 Restricted Stock Units (RSUs) and subsequent sale of 454 shares for tax withholding purposes at $95.82 per share. Following these transactions, Sakys directly owns 15,044 shares and indirectly holds 100 shares as custodian for his children.
Mesa Laboratories (NASDAQ:MLAB) reported insider trading activity through a Form 4 filing for SVP Operations Brian David Archbold. The transactions occurred on June 21, 2025, involving restricted stock units (RSUs). Archbold acquired 844 shares at $95.82 per share through RSU conversion and subsequently disposed of 385 shares at the same price, likely for tax withholding purposes. Following these transactions, Archbold holds 2,407 shares directly.